By: IPP Bureau
Last updated : April 20, 2026 1:00 pm
Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery
Vas Narasimhan, Chief Executive Officer of Novartis, has been appointed to the Board of Directors of Anthropic, marking a notable convergence of global healthcare leadership and advanced artificial intelligence innovation.
Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery, clinical development, and healthcare delivery.
His experience leading Novartis through a period of digital and data-driven transformation is expected to bring valuable strategic insight to Anthropic as it scales its AI capabilities and expands into enterprise and scientific applications.
At Novartis, Narasimhan has been instrumental in sharpening the company’s focus on innovative medicines while accelerating the adoption of data science and AI across research and operations. His addition to Anthropic’s board signals a broader trend of cross-industry collaboration, particularly between life sciences and frontier AI companies.
Anthropic, known for its work in building safe and reliable AI systems, continues to strengthen its leadership bench as it navigates rapid growth and increasing global interest in generative AI technologies.
The move also highlights how pharmaceutical leaders are playing a more active role in shaping the future of AI, especially in areas such as precision medicine, predictive analytics, and next-generation therapeutics.